[The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage â
¡~â
¢ non-small cell lung cancer].
Zhonghua Zhong Liu Za Zhi
; 42(6): 480-485, 2020 Jun 23.
Article
in Zh
| MEDLINE
| ID: mdl-32575944
ABSTRACT
Objective:
To explore the safety and therapeutic effect of programmed death 1 (PD-1) antibody combined with chemotherapy as a neoadjuvant therapy for patients with stage â ¡ to â ¢ non-small cell lung cancer (NSCLC).Methods:
Thirteen patients, who had been diagnosed as stage â ¡-â ¢ NSCLC and received PD-1 inhibitor plus chemotherapy as a neoadjuvant treatment in National Cancer Center/Cancer Hospital were recruited. The patients received consecutive neoadjuvant chemotherapy for 21 days as a cycle and the therapeutic efficacy was evaluated after two cycles.Results:
At the last time of follow-up on December 2, 2019, the objective response rate (ORR) and disease control rate (DCR) of these patients were 61.5% (95% CI 30.9%-92.1%) and 100%, respectively. The downregulation rate of disease stage was 61.5% (8/13). The resectable rate was 38.5% (5/13), among them, the major pathologic response (MPR) was 60.0% (3/5) and the complete pathologic response (CPR) was 20.0% (1/5). The neoadjuvant chemotherapy displayed a low incidence of adverse reaction. The main grade 3 to 4 toxicities were neutropenia (38.5%) and leukopenia (23.1%). There was no significant immune-related toxicity. The safety and tolerability of perioperative period of patients underwent resection were promising.Conclusions:
Immunotherapy combined with chemotherapy as a neoadjuvant treatment is an effective, low-toxicity treatment manner, which has perioperative safety and high rate of MPR for patients with resectable NSCLC. It is a promising treatment option for patients with stage â ¡ to â ¢ NSCLC.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Neoadjuvant Therapy
/
Programmed Cell Death 1 Receptor
/
Lung Neoplasms
Limits:
Humans
Language:
Zh
Journal:
Zhonghua Zhong Liu Za Zhi
Year:
2020
Type:
Article
Affiliation country:
China